

Cite this: *Chem. Sci.*, 2023, 14, 5774

All publication charges for this article have been paid for by the Royal Society of Chemistry

## *In vivo* biocompatibility of ZIF-8 for slow release via intranasal administration†

Sneha Kumari,<sup>a</sup> Thomas S. Howlett,<sup>a</sup> RYanne N. Ehrman,<sup>a</sup> Shailendra Koirala,<sup>a</sup> Orikeda Trashi,<sup>a</sup> Ikeda Trashi,<sup>a</sup> Yalini H. Wijesundara<sup>a</sup> and Jeremiah J. Gassensmith<sup>a,b</sup>

Zeolitic imidazolate framework-8 (ZIF-8) is becoming popular in research for its potential in antigen protection and for providing a thermally stable, slow-release platform. While papers applying this material for immunological applications are aplenty in the literature, studies that explore the biosafety of ZIF-8 in mammals—especially when administered intranasally—are not well represented. We checked the body clearance of uncoated and ZIF-8-coated liposomes and observed that the release slowed as ZIF-8 is easily degraded by mucosal fluid in the nasal cavity. We delivered varying doses of ZIF-8, checked its short- and long-term effects on diagnostic proteins found in blood serum, and found no noticeable differences from the saline control group. We also studied their lung diffusing capacity and tissue morphology; neither showed significant changes in morphology or function.

Received 28th January 2023  
Accepted 28th April 2023

DOI: 10.1039/d3sc00500c

rsc.li/chemical-science

## Introduction

Vaccines are a two-hundred-year-old technology that, despite new preparations and novel formulations, still require stable low-temperature storage conditions and delivery *via* needle and syringe.<sup>1,2</sup> Injections are one of the most frequently cited issues for poor compliance with vaccines; yet, developing alternatives is complicated because vaccines are made mainly of delicate biomolecules or lipid nanoparticles. Further, recent work has found that alternative delivery approaches can promote more robust protective immune responses, particularly in diseases that affect mucosal tissues. For instance, Forsyth *et al.* compared different UTI vaccine candidates through several delivery methods and found intranasally vaccinated groups to have the lowest bacterial load post-challenge.<sup>3</sup> The potential for exploration in this field is immense; not only can varying the delivery route help exploit mucosal immunity for various diseases, but it can also be pertinent, especially in vaccine development targeting respiratory infections like tuberculosis and respiratory syncytial virus.<sup>4</sup> Xing *et al.* also demonstrate a comparative study between intranasal and intramuscular administration of a tuberculosis vaccine, and the intranasally vaccinated group had better survival rates post-challenge.<sup>5</sup> Another significant advantage of exploring intranasal delivery of

vaccines is that it is easier to administer for non-medical personnel by being needle-free. This will help in vaccination drives where doctors and nurses are scarce, provide a pain-free experience, reduce biohazardous waste, and prevent cross-contamination through needles.

Targeting the mucosa can boost the efficacy of certain vaccines and combining these effects with a slow-release system can enhance the formulation's overall performance. Presently, however, intranasal delivery systems that prolong antigen residence are few and far between and almost non-existent for lipid-based systems.<sup>6,7</sup> Of all the methods being explored to build slow-release systems, biomimetic mineralization—encapsulation of natively folded biomacromolecules—within metal-organic frameworks (MOFs) shows great promise as they protect antigen integrity along with a slow-release platform. MOFs are self-assembling, low-density coordination polymers and a variety of them have been explored for biomaterial protection in the recent past.<sup>8–11</sup> In particular, zeolitic imidazolate frameworks (ZIFs)—a class of MOF made from interconnected ligands bridged by zinc ions—have emerged as the frontrunner candidate amongst all MOFs owing to their ease of synthesis in biofriendly conditions, ability to grow on a wide variety of biomaterial surfaces while protecting their surface motifs, and improved thermal stability.<sup>12,13</sup> ZIFs are unique as polymeric materials due to their kinetic lability; phosphate and carbonate salts, or albumin-rich environments readily pull the zinc from the framework causing it to dissolve completely, returning the original antigen to its pristine state.<sup>14,15</sup> ZIF's versatility in capturing, preserving, and releasing antigens is exceptional and has been used to encapsulate whole viruses,<sup>16,17</sup> bacteria,<sup>18</sup> proteins,<sup>19,20</sup> DNA,<sup>21,22</sup> RNA,<sup>23</sup> yeast,<sup>24</sup> liposomes,<sup>25,26</sup>

<sup>a</sup>Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd., Richardson, TX 75080, USA. E-mail: Sneha.kumari@utdallas.edu; gassensmith@utdallas.edu

<sup>b</sup>Department of Biomedical Engineering, The University of Texas at Dallas, 800 West Campbell Rd., Richardson, TX 75080, USA

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3sc00500c>

enzymes,<sup>27,28</sup> glycans,<sup>29</sup> and carbohydrates.<sup>30</sup> We have recently shown that ZIF-encapsulated formulations exhibit a depot effect, which significantly enhances the efficacy of vaccine models.<sup>1,31,32</sup> Additionally, MOF encapsulation of fragile biomaterials stabilizes them thermally, reducing the cost of vaccine transportation, which would otherwise need to be shipped and stored in  $-20\text{ }^{\circ}\text{C}$  (sometimes even  $-80\text{ }^{\circ}\text{C}$ ) freezers.

While considerable progress has been made in studying the applicability of ZIF-8 for antigen protection and slow release, ZIF-8 is a relatively new platform for antigen delivery, and questions about its compatibility with mucosal surfaces still need to be answered. While some papers shed light on the biosafety of other MOFs *in vivo*,<sup>33–35</sup> rigorous studies assessing the biocompatibility of ZIF-8 in mammals, particularly when delivered intranasally, have yet to be done. In this paper, we evaluate the dose-dependent toxicity of ZIF-8 in mice delivered *via* intranasal administration. We look at its systemic effects and changes occurring in the respiratory system, along with other adjacent studies. Specifically, we show that ZIF-8 nanoparticles delivered intranasally have no long-term impact on the nasal mucosal surfaces or the respiratory system, and we find no evidence of dysfunction in major organs. Finally, we show that intranasal delivery of ZIF-8-coated liposomes enhances their residency in the sinuses four-fold.

## Results and discussion

### Material characterization

We synthesized nano-sized ZIF-8 and characterized it using scanning electron microscopy (SEM) (Fig. 1A) and powder X-ray diffraction (PXRD) (Fig. 1C) for dose-dependent studies of the MOF itself. Since ZIF-8 is intended to be used as a protective coating for biomaterials, we also prepared liposomes encapsulated in ZIF-8 (Lip@Z) with an encapsulation efficiency of 99% as a model. The liposomes were characterized using dynamic

light scattering (Fig. S1†) and transmission electron microscopy (Fig. S2†). Lip@Z was also characterized by SEM (Fig. 1B), which showed the particle sizes and morphologies consistent with nano-sized ZIF-8. The PXRD (Fig. 1C) likewise presents clear evidence that the incorporation of liposomes does not significantly affect the crystallinity of the system. For imaging-based studies, the liposomes were filled with fluorescent dye cyanine-7 (Lip(Cy7)) as cargo and were subsequently encapsulated in ZIF-8 (Lip(Cy7)@Z). Lip(Cy7) were characterized by DLS (Fig. S3†), and Lip(Cy7)@Z by PXRD (Fig. S4†). Additionally, epifluorescence microscopy (Fig. 1D) was used to show that Lip(Cy7) was incorporated into the ZIF-8 crystals. We then confirmed whether our formulation holds up to the literature standards of ZIF's ability to provide protection to the encapsulated biomaterial. We heated Lip@Z and pristine liposomes in a  $60\text{ }^{\circ}\text{C}$  bath for 30 m, after which Lip@Z was exfoliated using EDTA to remove the ZIF-8 coating. The pristine liposomes, heated liposomes, and liposomes recovered from heated Lip@Z were checked for size using DLS. We confirmed that the ZIF-8 coating effectively retained the original size and prevented aggregation or significant size changes in these liposomes (Fig. S5†).

### Cytotoxicity and tissue residency

Before performing *in vivo* experiments, cytotoxicity assays for ZIF-8 and Lip@Z were carried out on the A549 human lung adenocarcinoma (Fig. 2A), LLC1 Lewis lung carcinoma (Fig. S6†), and OE33 oesophageal carcinoma cell lines (Fig. S7†). In the A549 model, doses up to  $300\text{ }\mu\text{g mL}^{-1}$  were relatively non-toxic, and an  $\text{IC}_{50}$  could not be established for both ZIF-8 and Lip@Z in this cell line up to 1 mg. In the LLC1 model,  $\text{IC}_{50}$  of ZIF-8 was calculated as  $70.52 \pm 3.46\text{ }\mu\text{g mL}^{-1}$  and Lip@Z as  $69.15 \pm 2.54\text{ }\mu\text{g mL}^{-1}$ . The OE33 model gave an  $\text{IC}_{50}$  of  $73.64 \pm 10.7\text{ }\mu\text{g mL}^{-1}$  for ZIF-8 and  $71.11 \pm 4.7\text{ }\mu\text{g mL}^{-1}$  for Lip@Z. We next assessed how long these materials would remain within the nasal cavity following intranasal administration in BALB/c mice ( $n = 3$ ). The corresponding amount of encapsulated Lip(Cy7) was used as a control group ( $n = 3$ ) to study the difference the ZIF-8 coating provides to tissue residency. We observed that the material cleared out of the body in under 18 h for the Lip(Cy7)@Z group, significantly improving over the control group that lasted under 4 h (Fig. 2C). The fluorescent intensities were plotted, and the half-life of the Lip(Cy7)@Z group was calculated to be  $\sim 9\text{ h}$ , which is over four times the half-life of free liposomes ( $\sim 2.1\text{ h}$ ) (Fig. 2B). To assess if the zinc was bioaccumulating in major organs following dosing, *ex vivo* analysis 18 h post administration was conducted *via* inductively coupled plasma mass spectrometry. No significant elevation in zinc levels was observed in the liver, spleen, kidneys, and lungs compared to the liposome-only control group, indicating the zinc was likely excreted (Fig. S8†). It is worth mentioning that zinc homeostasis is highly controlled in mammals.<sup>36</sup>

### Biocompatibility studies *in vivo*

We emulated a typical *in vivo* vaccination experiment with three doses to assess how repeated exposure to the material would




Fig. 1 (A) SEM of ZIF-8 (scale = 300 nm), (B) SEM of Lip@Z (scale = 300 nm), (C) PXRD of ZIF-8 and Lip@Z along with simulated ZIF-8 for reference, (D) epifluorescence micrograph of Lip(Cy7)@Z (scale = 200  $\mu\text{m}$ ).






Fig. 2 (A) Cytotoxicity of ZIF-8 and Lip@Z (4 h) in A549 cells (B) time profile of quantified fluorescence (C) fluorescence images of mice until 18 h.

affect the mucosa of the sinuses as well as liver and kidney function. ZIF-8 was administered intranasally in 4–6 week-old C57BL/6 female mice in three successive doses, each one week apart. The groups ( $n = 4$ ) were divided by the amount of ZIF-8 delivered, which ranged from 50 to 1000  $\mu\text{g}$ . Two more groups were added to simulate a more application-based approach. A liposome-only group ( $n = 4$ ) composed of FDA-approved lipids was added as a reference nanocarrier. Lip@Z group was added as an example biocomposite material ( $n = 4$ ) and administered at 1000  $\mu\text{g}$ . In all cases, blood was collected submandibular on day 1 (one day after the first dose) and day 21 (one day after the third dose) to quantify common serum proteins and enzymes to analyze whether the administered ZIF-

8 has a systemic effect on their clinical chemistry. We chose to study albumin, urea, and bilirubin among the serum proteins and alkaline phosphatase (ALP), aspartate aminotransferase (AST), and  $\gamma$ -glutamyl transferase (GGT) as representative serum enzymes which collectively serve as biomarkers indicating kidney and liver dysfunction.<sup>37,38</sup> We observed no noticeable pattern in changes in protein (Fig. 3A) or enzyme (Fig. 3B) levels, and any fluctuations were non-significant with respect to the saline (PBS) control group.

It is important to ensure that directly administering particles into the nasal cavity does not affect the function of the




Fig. 3 (A) Levels of albumin, urea (left axis), and bilirubin (right axis) on day 1 and day 21, (B) levels of ALP, AST (left axis), and GGT (right axis) on day 1 and day 21. On both charts, 50 to 1000 indicate the dose of ZIF-8 administered in  $\mu\text{g}$ .




Fig. 4 (A) Experimental scheme for DFCO test (B) DFCO measurements for all groups. (B) DFCO measurements for each group. (+) stands for positive control, mouse euthanized and used immediately after cervical dislocation, and (−) stands for the saline group. 50 to 1000 indicate the dose of ZIF-8 administered in  $\mu\text{g}$ . (+) and (−) are significantly different, with  $p = 0.02$ . No significant difference exists between (−) and all the ZIF-8, liposome, and Lip@Z groups.





respiratory system. A common test used in clinical settings is diffusing capacity of the lungs for carbon monoxide (DLCO); this test uses a gas mix containing small percentages of carbon monoxide and an inert tracer gas to measure the diffusing capacity of the lungs by the amount of carbon monoxide absorbed. This test is challenging to perform in small animal models for practical considerations. Limjunyawong *et al.* developed a close analog for this test, which measures the diffusion factor for carbon monoxide (DFCO) in mice (Fig. 4A).<sup>39</sup> We used this methodology—and modified this test to be less invasive—to determine how three intranasally delivered ZIF-8 doses affect lung function. The mice from the previous experiment were used to record DFCO measurements ( $n = 4$ ).

All experimental groups (including Lip and Lip@Z) had similar DFCO values to that of the negative control (PBS) group,

as no significance was obtained between any groups (Fig. 4B). For positive control of damage in the respiratory system, we euthanized mice ( $n = 3$ ) through isoflurane overdose followed by cervical dislocation and carried out their DFCO measurement immediately after they were euthanized. The measurement of the euthanized positive control group is significantly different compared to the negative control group. The absolute values of negative and positive control mice also correlate with the literature values.<sup>40</sup>

Once the mice were sacrificed after blood draws and DFCO studies, we extracted their nasal turbinates, trachea, and lungs to assess tissue damage using hematoxylin and eosin (H&E) staining. For the nasal turbinates (Fig. 5A), we did not observe any distinct thinning of the olfactory epithelium, presence of Splendor-Hoepli bodies, or atrophy in turbinate structure




Fig. 5 H&E for (A) turbinates, (B) arrows indicating goblet cells inside the above turbinates, (C) lungs, (D) trachea.




Fig. 6 SEM micrographs of cilia present in the inner lining of the trachea.

across any groups, including the 1000  $\mu\text{g}$  dose. One marked difference in the groups with higher doses of ZIF-8 and the 1000  $\mu\text{g}$  Lip@Z group was an increase in goblet cells, often observed after short-term exposure to a mild irritant (Fig. 5B). However, a similar density of goblet cells was also observed in the liposome group, indicating that exposure to a variety of nano-carriers triggers mild irritation, and the issue is not specific to ZIF-8. In the lungs (Fig. 5C), we observed little to no detachment of viable cells from the epithelial surface, no observable neutrophil infiltration in alveoli or enlarged, foamy macrophages, or any significant amount of fibrosis. There were no major pathological changes concerning the thickness of the epithelial lining or density of nuclei in the trachea across any groups (Fig. 5D).

Additional analysis of the same trachea samples was done by observing the cilia along its inner lining under SEM (Fig. 6). The cilia in the 1 mg ZIF-8, liposome, and 1 mg Lip@Z groups appear to be of similar density compared to the saline group. The cilia also do not seem to show any distinct abnormalities like what other groups have previously observed and published in the literature.<sup>41</sup>

## Conclusion

In this work, we explored the *in vivo* biosafety of ZIF-8 for application in intranasal vaccine delivery. We found that mice could tolerate up to 1 mg of ZIF delivered intranasally—significantly more than would be required for most vaccine applications. After investigating the systemic effects, respiratory function, and tissue pathology, we conclude that the material is safe for intranasal delivery in animal models. Additionally, we have shown that we can slow the release of liposomes in the nasal cavity, which can be exploited for immunological benefits when developing vaccine formulations.

## Materials and methods

### Materials

18 : 0 PC (DSPC) 1,2-distearoyl-*sn*-glycero-3-phosphocholine and 18 : 1 ( $\Delta 9$ -*cis*) PE (DOPE) 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine were purchased from Avanti Polar Lipids. MOPS 3-(4-morpholino) propane sulfonic acid, TCEP tris(2-carboxyethyl) phosphine, sodium chloride, chloroform, nitric acid (trace metal grade), hydrochloric acid, and glacial acetic acid were purchased from Thermo Fisher Scientific. Cyanine-7 was synthesized in-house; characterization has been included in the ESI (Fig. S9 to S15<sup>†</sup>). Zinc acetate dihydrate, 2-methylimidazole, ethanol (100%), histological grade xylenes, Harris hematoxylin solution (modified), Scott's tap water substitute concentrate, eosin Y aqueous solution, L-glutamine solution, bromocresol green (BCG) albumin assay kit, alkaline phosphatase assay kit, aspartate aminotransferase (AST) activity assay, bilirubin assay kit,  $\gamma$ -glutamyltransferase (GGT) activity colorimetric assay kit, and urea assay kit were purchased from Millipore Sigma. HyClone phosphate buffered saline solution, HyClone Dulbecco's modified eagle's medium (DMEM), HyClone RPMI 1640 medium, and penicillin-streptomycin were purchased from Cytiva. FB Essence was purchased from Avantor. Cell culture grade dimethyl sulfoxide (DMSO) and histological grade ethanol (95%) were purchased from Bioworld. Deep blue cell viability kit was purchased from Biolegend. 0.3% carbon monoxide + 0.3% neon + 21% oxygen + balance nitrogen gas mix cylinder was purchased from SCI Analytical Laboratories. Isoflurane solution was purchased from Covetrus. Cytoseal 60 was purchased from electron microscopy sciences.

### Cells, animals, and ethics statement

A549 and LLC-1 cells were received as gifts from Dr Laurentiu Pop (Department of Radiation Oncology, UT Southwestern). OE33 cells were received as a gift from Dr David Wang (Harold C. Simmons Comprehensive Cancer Center, UT Southwestern). Female C57BL/6 mice (4–6 weeks) and male BALB/c mice (10–12 weeks) were purchased from Charles River Laboratories (Wilmington, MA). All *in vivo* experiments were performed in strict accordance under protocol #19-06, approved by the University of Texas at Dallas Institutional Animal Care and Use Committee (IACUC).

### Instruments

PXRD spectra were measured using a Rigaku SmartLab X-ray diffractometer. SEM micrographs were taken using Zeiss Supra 40. Liposomes were extruded using Avanti Mini Extruder and pelleted down using Sorvall MX-120 micro-ultracentrifuge. Fluorescence spectra were recorded using a Horiba Fluorolog fluorimeter. DLS measurements were carried out using Malvern Analytical Zetasizer Nano ZS. TEM micrographs were taken JEOL 1400 transmission electron microscope. Cell counting was carried out using Thermo Countess II. Colorimetric and fluorescence-based assays were analyzed using a Biotek Synergy H4 Hybrid microplate reader. Epifluorescence images were taken on EVOS FL digital inverted fluorescence microscope.





Live animal imaging was done on IVIS Lumina III. Zinc concentration in organs was quantified using Agilent 7900 ICP-MS. Lung capacity gas samples were analyzed using Agilent GCMS. Tissue samples were washed on a solvent gradient using Leica ASP300 S. Paraffin embedding was carried out on HistoCore ARCADIA. Tissue samples were sliced using a Leica RM2235 microtome. H&E slides were imaged using Olympus VS120 virtual slide microscope.

### Synthesis of ZIF-8, liposomes, and ZIF-8-encapsulated liposomes

ZIF-8 was synthesized using zinc acetate and 2-methylimidazole, whose final concentrations in DI water were 20 mM and 1.28 M, respectively. The reaction was carried out for 3 h at RT and then washed twice. For washing, the product was centrifuged at  $4000\times g$  for 15 min at RT, and the supernatant was exchanged with DI water. After washing, ZIF-8 was dried under vacuum conditions overnight to obtain a crystalline solid. Liposomes were synthesized and encapsulated in ZIF-8 using a previously published protocol (encapsulation with 20 mM zinc acetate and 640 mM 2-methylimidazole).<sup>26</sup>

### Cell culture, cytotoxicity measurement, and IC<sub>50</sub> determination

A549, LLC-1, and OE33 cells were cultured in DMEM supplemented with FB essence, L-glutamine, and penicillin-streptomycin in T75 flasks. All cells were grown at 37 °C, 5% CO<sub>2</sub> till 80% confluence. After detaching the cells with trypsin, the trypsin was neutralized using DMEM. Cells were counted and seeded in a 96-well plate (25 000 cells per well). ZIF-8 and Lip@Z were added in concentrations ranging from 0  $\mu\text{g mL}^{-1}$  to 1000  $\mu\text{g mL}^{-1}$  for A549, 0  $\mu\text{g mL}^{-1}$  to 160  $\mu\text{g mL}^{-1}$  for LLC-1, and 0  $\mu\text{g mL}^{-1}$  to 250  $\mu\text{g mL}^{-1}$  for OE33. The cells were then incubated at 37 °C, 5% CO<sub>2</sub> for 4 h. 30 min before 4 h time point, 10  $\mu\text{L}$  of lysis buffer was added to appropriate wells as a negative control. At 4 h, 10  $\mu\text{L}$  of the deep blue cell viability kit dye was added to each well and incubated for 4 h. The plate was read for fluorescence at an excitation of 530 nm and an emission of 590 nm. % viability was normalized to media only and lysed cell controls and data is presented as average  $\pm$  standard deviation ( $N = 4$  with outlier analysis done in GraphPad Prism software with Grubbs' method). IC<sub>50</sub> was determined using linear regression function in excel.

### Synthesis of Cy7 dye

(i) Synthesis of 2,4-dinitrophenyl *p*-toluenesulfonate: 2,4-dinitrophenol (2.5 g, 13.58 mmol) was dissolved in dichloromethane (50 mL), *p*-toluenesulfonyl chloride (2.84 g, 14.93 mmol), and triethylamine (3.45 g, 33.95 mmol) were added successively, and the mixture was stirred for 16 h at room temperature. 50 mL water was added, and the mixture was extracted with dichloromethane ( $3 \times 30$  mL). The organic phase was washed with NaHCO<sub>3</sub> ( $3 \times 30$  mL), brine ( $3 \times 30$  mL), and the organic fraction was evaporated under reduced pressure. The crude product was purified by trituration with hot methanol (30 mL) to give the pure product (white solid). Yield: 2.57 g

(56%). <sup>1</sup>H NMR (500 MHz, d<sub>6</sub>-DMSO):  $\delta$  (ppm) 8.83 (d,  $J = 2.8$  Hz, 1H), 8.69–8.47 (m, 1H), 7.91–7.71 (m, 2H), 7.68–7.35 (m, 3H), 2.46 (s, 3H).

(ii) Synthesis of 1-(2,4-dinitrophenyl)-4-(methoxycarbonyl)pyridin-1-ium *p*-toluenesulfonate: a mixture of 2,4-dinitrophenyl *p*-toluenesulfonate (2.57 g, 2.57 mmol) and methyl isonicotinate (0.94 g, 6.90 mmol) were dissolved in toluene (7 mL mmol<sup>-1</sup>). The reaction was refluxed for 16 h and left to cool to room temperature. The precipitate was filtered, washed with toluene ( $2 \times 5$  mL) and Et<sub>2</sub>O ( $2 \times 5$  mL), and dried. Yield: 0.78 g (24%). <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  9.59 (dd,  $J = 6.7$ , 1.6 Hz, 2H), 9.12 (t,  $J = 1.8$  Hz, 1H), 8.98 (dd,  $J = 8.7$ , 2.5 Hz, 1H), 8.88–8.75 (m, 2H), 8.40 (d,  $J = 8.7$  Hz, 1H), 7.45 (dd,  $J = 8.2$ , 1.9 Hz, 2H), 7.10 (d,  $J = 7.8$  Hz, 2H), 4.05 (s, 3H), 2.29 (s, 3H).

(iii) Synthesis of 4-carboxy-1-(2,4-dinitrophenyl)pyridin-1-ium *p*-toluenesulfonate: the carboxylic acid was prepared by hydrolysis of 1-(2,4-dinitrophenyl)-4-(methoxycarbonyl)pyridin-1-ium *p*-toluenesulfonate in aqueous HCl (6 M, 50 mL) at 50 °C for 36 h. The solvent was evaporated at reduced pressure, and the crude product was purified by recrystallization from methanol (50 mL) to give the pure product as a white solid. Yield: 0.68 g (91%). <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  9.59 (dd,  $J = 6.7$ , 1.6 Hz, 2H), 9.12 (t,  $J = 1.8$  Hz, 1H), 8.98 (dd,  $J = 8.7$ , 2.5 Hz, 1H), 8.85–8.70 (m, 2H), 8.40 (d,  $J = 8.7$  Hz, 1H), 7.45 (dd,  $J = 8.2$ , 1.9 Hz, 2H), 7.10 (d,  $J = 7.8$  Hz, 2H), 2.29 (s, 3H).

(iv) Synthesis of 3-(2,3,3-trimethyl-3*H*-indol-1-ium-1-yl)propane-1-sulfonate: 2,3,3-trimethylindoline (3.00 g, 18.84 mmol) and 1,3-propane sulfone (2.30 g, 18.84 mmol) was stirred at 120 °C for 1.5 h. Methanol was added to the reaction mixture and stirred at room temperature for 0.5 h. Ethyl acetate and cyclohexane were added. The white precipitate was filtered and washed with ethyl acetate. The solid was dried under reduced pressure to afford 3-(2,3,3-trimethyl-3*H*-indol-1-ium-1-yl)propane-1-sulfonate (4.25 g, 15.12 mmol, 80%) as a white solid. <sup>1</sup>H NMR (500 MHz, MeOD):  $\delta$  = 8.06–8.00 (m, 1H), 7.83–7.77 (m, 1H), 7.65–7.59 (m, 2H), 4.76 (t,  $J = 8.0$  Hz, 2H), 3.03 (s, 2H), 2.62 (t,  $J = 6.6$  Hz, 3H), 2.40–2.29 (m, 2H), 1.62 (s, 6H) ppm.

(v) Synthesis of sodium 3-((1*E*,3*Z*,5*E*)-4-carboxy-7-((*E*)-3,3-dimethyl-1-(3-sulfonatopropyl)indolin-2-ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-3*H*-indol-1-ium-1-yl)propane-1-sulfonate: 4-carboxy-1-(2,4-dinitrophenyl)pyridin-1-ium *p*-toluenesulfonate (250 mg, 0.54 mmol) and 4-bromoaniline (250 mg, 0.54 mmol) were dissolved in methanol (7 mL mmol<sup>-1</sup>), and the mixture was stirred at room temperature for 0.5 h. Next, 3-(2,3-dimethyl-3*H*-indol-1-ium-1-yl)propane-1-sulfonate (457 mg, 1.63 mmol) and sodium acetate (265 mg, 3.24 mmol) were added, and the reaction mixture was stirred for additional 16 h at room temperature. Afterward, Et<sub>2</sub>O (21 mL mmol<sup>-1</sup>) was added, and the mixture was placed in the freezer (−16 °C). The resulting precipitate was filtered and purified by column chromatography (silica gel, dichloromethane/methanol, 10 : 1, then switched to 5 : 1). Yield: 161 mg (45%). Deep green solid. <sup>1</sup>H NMR (600 MHz, MeOD)  $\delta$  8.58–8.56 (m, 1H), 8.14 (d,  $J = 13.4$  Hz, 2H), 7.84–7.83 (m, 1H), 7.44 (s, 1H), 7.38 (d,  $J = 4.1$  Hz, 4H), 7.22–7.20 (m, 2H), 6.40 (d,  $J = 13.4$  Hz, 4H), 4.29–4.26 (m, 4H), 2.97 (d,  $J = 6.9$  Hz, 4H), 2.21 (d,  $J =$



7.8 Hz, 4H), 1.67 (s, 12H). For  $C_{34}H_{38}N_2NaO_8S_2^- [M - H^-]$  690.2, found 691.2.

### Tissue residency and biodistribution of intranasally delivered ZIF-8

Male BALB/c mice were shaved using Nair around the lower half of their face and chest. Three groups ( $n = 3$  each) were administered with 1 mg Lip(Cy7)@Z, and Lip(Cy7) made of 1 mg lipids and saline, respectively, *via* a micropipette. All volumes were kept under 30  $\mu$ L. Animals were imaged before administration and after 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 18 h – which is when the fluorescence disappeared for groups. Raw data were processed using Living Image<sup>®</sup> 4.7.3 software.

### Serum protein and enzyme quantification assay

Submandibular blood collection was carried out on day 1 and day 21 from mice. 2  $\mu$ L of each serum sample was used to quantify albumin, bilirubin, urea, ALP, AST, and GGT using commercially available colorimetric kits following the manufacturer's instructions.

### DFO test for lung capacity

A balloon was filled with a gas mix (0.3% CO, 0.3% Ne, 21% O<sub>2</sub>, balance N<sub>2</sub>) and sealed with a rubber septum. The gas mix was collected in a 1 mL syringe and was endotracheally administered into anesthetized mice using a 14 G catheter. After 9 seconds, the syringe plunger was pulled, and a gas sample was collected. The sample was injected into GCMS for analysis. DFCO was calculated using a published protocol.<sup>40</sup>

### Histological analysis of organs

Mice were sacrificed, and their lungs, trachea, and nasal turbinates were collected. Each organ was added to 30 mL of 4% paraformaldehyde in 1 $\times$  PBS and left under shaking conditions for 48 hours. Organs were transferred to 70% ethanol in MilliQ in cassettes. Turbinates were sent for further processing to Histopathology Core, University of Texas, Southwestern. Lungs and trachea were embedded in paraffin and cooled over ice. Embedded organs were cut into 5  $\mu$ m thick samples and collected on positively charged slides. Once dried, slides were dipped in (i) xylenes (10 min), (ii) xylenes (10 min), (iii) xylenes (10 min), (iv) 100% ethanol (5 min), (v) 100% ethanol (5 min), (vi) 95% ethanol (5 min), (vii) 95% ethanol (5 min), (viii) 70% ethanol (5 min), (ix) 70% ethanol (5 min), (x) 50% ethanol (10 min), (xi) tap water (5 min), (xii) hematoxylin (2 min), (xiii) tap water (10 dunks), (xiv) tap water (10 dunks), (xv) tap water (10 dunks), (xvi) accumulate (0.75 mL HCl + 300 mL 70% ethanol) (4 dunks), (xvii) tap water (10 dunks), (xviii) tap water (10 dunks), (xix) Scott's tap water (1 min), (xx) 95% ethanol (5 min), (xxi) eosin acidified with 0.5% glacial acetic acid (1 min), (xxii) 95% ethanol (10 dunks), (xxiii) 100% ethanol (1 min), (xxiv) 100% ethanol (1 min), (xxv) xylenes (5 min), (xxvi) xylenes (5 min), and (xxvii) xylenes (5 min) sequentially. Stained samples were sealed with a cover slip and imaged under a brightfield microscope.

### Visualization of cilia

Previously embedded tracheas were cut into 5  $\mu$ m thick samples and collected on positively charged slides. For the dewaxing and rehydration, slides were dipped in (i) xylenes (10 min), (ii) xylenes (10 min), (iii) 100% ethanol (5 min), (iv) 100% ethanol (5 min), (v) 95% ethanol (5 min), (vi) 95% ethanol (5 min), (vii) 70% ethanol (5 min), and (viii) 50% ethanol (5 min) sequentially. Slides were then sputtered with gold and imaged using SEM.

### Data availability

All study data are included in the article and/or the ESI.<sup>†</sup> Raw data is available in open science framework ([https://osf.io/z3w92/?view\\_only=b05edce708284e3c967b18059e156322](https://osf.io/z3w92/?view_only=b05edce708284e3c967b18059e156322)).

### Author contributions

Conceptualization: S. Kumari, J. J. G. Methodology: S. Kumari, T. S. H. Investigation: S. Kumari, T. S. H., R. N. E., S. Koirala, O. T., I. T., Y. H. W. Writing – original draft: S. Kumari. Writing – review & editing: S. Kumari, J. J. G. Supervision: J. J. G. Funding acquisition: J. J. G.

### Conflicts of interest

The authors declare that they have no competing interests.

### Acknowledgements

S. Kumari would like to thank Dr Fang Bian of the Mass Spectrometry Core for her expertise and help with the GCMS, Jashkaran Gadhvi for arranging the H&E staining setup, and UT Southwestern Pathology Core for sectioning and initial assessment of turbinate specimens. J. J. G. acknowledges the National Science Foundation (Grant No. DMR-2003534) and the Welch Foundation (Grant No. AT-1989-20190330) for their support and funding.

### References

- 1 M. A. Luzuriaga, A. Shahrivarkevishahi, F. C. Herbert, Y. H. Wijesundara and J. J. Gassensmith, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2021, **13**, e1735.
- 2 R. P. Welch, H. Lee, M. A. Luzuriaga, O. R. Brohlin and J. J. Gassensmith, *Bioconjugate Chem.*, 2018, **29**, 2867–2883.
- 3 V. S. Forsyth, S. D. Himpsl, S. N. Smith, C. A. Sarkissian, L. A. Mike, J. A. Stocki, A. Sintsova, C. J. Alteri and H. L. T. Mobley, *mBio*, 2020, **11**, e00555–20.
- 4 D. Cahn, M. Amosu, K. Maisel and G. A. Duncan, *Nat. Rev. Bioeng.*, 2023, **1**, 83–84.
- 5 Z. Xing, C. T. McFarland, J.-M. Sallenave, A. Izzo, J. Wang and D. N. McMurray, *PLoS One*, 2009, **4**, e5856.
- 6 M. Zaman, S. Chandrudu and I. Toth, *Drug Delivery Transl. Res.*, 2013, **3**, 100–109.
- 7 Z. Lu, S. Bai, Y. Jiang, S. Wu, D. Xu, J. Zhang, X. Peng, H. Zhang, Y. Shi and G. Liu, *Small*, 2022, **18**, 2203952.



- 8 T.-Y. Tai, F. Sha, X. Wang, X. Wang, K. Ma, K. O. Kirlikovali, S. Su, T. Islamoglu, S. Kato and O. K. Farha, *Angew. Chem., Int. Ed.*, 2022, **61**, e202209110.
- 9 P. Li, S.-Y. Moon, M. A. Guelta, L. Lin, D. A. Gómez-Gualdrón, R. Q. Snurr, S. P. Harvey, J. T. Hupp and O. K. Farha, *ACS Nano*, 2016, **10**, 9174–9182.
- 10 Y. Chen, P. Li, J. A. Modica, R. J. Drouot and O. K. Farha, *J. Am. Chem. Soc.*, 2018, **140**, 5678–5681.
- 11 W. Yang, W. Liang, L. A. O'Dell, H. D. Toop, N. Maddigan, X. Zhang, A. Kochubei, C. J. Doonan, Y. Jiang and J. Huang, *JACS Au*, 2021, **1**, 2172–2181.
- 12 S. Li, M. Dharmarwardana, R. P. Welch, Y. Ren, C. M. Thompson, R. A. Smaldone and J. J. Gassensmith, *Angew. Chem., Int. Ed.*, 2016, **55**, 10691–10696.
- 13 K. Liang, R. Ricco, C. M. Doherty, M. J. Styles, S. Bell, N. Kirby, S. Mudie, D. Haylock, A. J. Hill, C. J. Doonan and P. Falcaro, *Nat. Commun.*, 2015, **6**, 7240.
- 14 M. A. Luzuriaga, C. E. Benjamin, M. W. Gaertner, H. Lee, F. C. Herbert, S. Mallick and J. J. Gassensmith, *Supramol. Chem.*, 2019, **31**, 485–490.
- 15 M. d. J. Velásquez-Hernández, R. Ricco, F. Carraro, F. T. Limpoco, M. Linares-Moreau, E. Leitner, H. Wiltse, J. Rattenberger, H. Schröttner, P. Frühwirth, E. M. Stadler, G. Gescheidt, H. Amenitsch, C. J. Doonan and P. Falcaro, *CrystEngComm*, 2019, **21**, 4538–4544.
- 16 M. A. Luzuriaga, R. P. Welch, M. Dharmarwardana, C. E. Benjamin, S. Li, A. Shahrivarkevishahi, S. Popal, L. H. Tuong, C. T. Creswell and J. J. Gassensmith, *ACS Appl. Mater. Interfaces*, 2019, **11**, 9740–9746.
- 17 S. Li, M. Dharmarwardana, R. P. Welch, C. E. Benjamin, A. M. Shamir, S. O. Nielsen and J. J. Gassensmith, *ACS Appl. Mater. Interfaces*, 2018, **10**, 18161–18169.
- 18 S. Li, X. Zhou, Z. Chen, F. C. Herbert, R. Jayawickramage, S. D. Panangala, M. A. Luzuriaga, S. B. Alahakoon, S. D. Diwakara, X. Meng, L. Fei, J. Ferraris, R. A. Smaldone and J. J. Gassensmith, *ACS Appl. Mater. Interfaces*, 2020, **12**, 11884–11889.
- 19 C. Wang, H. Sun, J. Luan, Q. Jiang, S. Tadepalli, J. J. Morrissey, E. D. Kharasch and S. Singamaneni, *Chem. Mater.*, 2018, **30**, 1291–1300.
- 20 Y. H. Wijesundara, F. C. Herbert, O. Trashy, I. Trashy, O. R. Brohlin, S. Kumari, T. Howlett, C. E. Benjamin, A. Shahrivarkevishahi, S. D. Diwakara, S. D. Perera, S. A. Cornelius, J. P. Vizuet, K. J. Balkus, R. A. Smaldone, N. J. De Nisco and J. J. Gassensmith, *Chem. Sci.*, 2022, **13**, 13803–13814.
- 21 A. Poddar, J. J. Conesa, K. Liang, S. Dhakal, P. Reineck, G. Bryant, E. Pereiro, R. Ricco, H. Amenitsch, C. Doonan, X. Mulet, C. M. Doherty, P. Falcaro and R. Shukla, *Small*, 2019, **15**, 1902268.
- 22 O. R. Brohlin, R. N. Ehrman, F. C. Herbert, Y. H. Wijesundara, A. Raja, A. Shahrivarkevishahi, S. D. Diwakara, R. A. Smaldone and J. J. Gassensmith, *ACS Appl. Nano Mater.*, 2022, **5**, 13697–13704.
- 23 A. Poddar, S. Pyreddy, F. Carraro, S. Dhakal, A. Russell, M. R. Field, T. S. Reddy, P. Falcaro, C. M. Doherty and R. Shukla, *Chem. Commun.*, 2020, **56**, 15406–15409.
- 24 L. Gan, M. d. J. Velásquez-Hernández, A. Emmerstorfer-Augustin, P. Wied, H. Wolinski, S. D. Zilio, M. Solomon, W. Liang, C. Doonan and P. Falcaro, *Chem. Commun.*, 2022, **58**, 10004–10007.
- 25 F. C. Herbert, S. S. Abeyrathna, N. S. Abeyrathna, Y. H. Wijesundara, O. R. Brohlin, F. Carraro, H. Amenitsch, P. Falcaro, M. A. Luzuriaga, A. Durand-Silva, S. D. Diwakara, R. A. Smaldone, G. Meloni and J. J. Gassensmith, *Nat. Commun.*, 2021, **12**, 2202.
- 26 S. Kumari, Y. H. Wijesundara, T. S. Howlett, M. Waliullah, F. C. Herbert, A. Raja, I. Trashy, R. A. Bernal and J. J. Gassensmith, *Proc. Natl. Acad. Sci. U. S. A.*, 2023, **120**, e2218247120.
- 27 N. K. Maddigan, O. M. Linder-Patton, P. Falcaro, C. J. Sumby, S. G. Bell and C. J. Doonan, *ACS Appl. Mater. Interfaces*, 2021, **13**, 51867–51875.
- 28 W. Liang, H. Xu, F. Carraro, N. K. Maddigan, Q. Li, S. G. Bell, D. M. Huang, A. Tarzia, M. B. Solomon, H. Amenitsch, L. Vaccari, C. J. Sumby, P. Falcaro and C. J. Doonan, *J. Am. Chem. Soc.*, 2019, **141**, 2348–2355.
- 29 M. d. J. Velásquez-Hernández, E. Astria, S. Winkler, W. Liang, H. Wiltse, A. Poddar, R. Shukla, G. Prestwich, J. Paderi, P. Salcedo-Abaira, H. Amenitsch, P. Horcajada, C. J. Doonan and P. Falcaro, *Chem. Sci.*, 2020, **11**, 10835–10843.
- 30 E. Astria, M. Thonhofer, R. Ricco, W. Liang, A. Chemelli, A. Tarzia, K. Alt, C. E. Hagemeyer, J. Rattenberger, H. Schroettner, T. Wrodnigg, H. Amenitsch, D. M. Huang, C. J. Doonan and P. Falcaro, *Mater. Horiz.*, 2019, **6**, 969–977.
- 31 M. A. Luzuriaga, F. C. Herbert, O. R. Brohlin, J. Gadhvi, T. Howlett, A. Shahrivarkevishahi, Y. H. Wijesundara, S. Venkitapathi, K. Veera, R. Ehrman, C. E. Benjamin, S. Popal, M. D. Burton, M. A. Ingersoll, N. J. De Nisco and J. J. Gassensmith, *ACS Nano*, 2021, **15**, 17426–17438.
- 32 F. Peng, Y. Xiang, H. Wang, Y. Hu, R. Zhou and Y. Hu, *Small*, 2022, **18**, 2204011.
- 33 T. Baati, L. Njim, F. Neffati, A. Kerkeni, M. Bouttemi, R. Gref, M. F. Najjar, A. Zakhama, P. Couvreur, C. Serre and P. Horcajada, *Chem. Sci.*, 2013, **4**, 1597–1607.
- 34 N. Abramenko, G. Deyko, E. Abkhalimov, V. Isaeva, L. Pelgunova, E. Krysanov and L. Kustov, *Int. J. Mol. Sci.*, 2021, **22**, 5568.
- 35 S. Lan, J. Zhang, X. Li, L. Pan, J. Li, X. Wu and S.-T. Yang, *Nanomaterials*, 2022, **12**, 3398.
- 36 J. C. King, D. M. Shames and L. R. Woodhouse, *J. Nutr.*, 2000, **130**, 1360S–1366S.
- 37 M. A. Riaz, Z. U. Nisa, A. Mehmood, M. S. Anjum and K. Shahzad, *Environ. Sci. Pollut. Res.*, 2019, **26**, 31111–31118.
- 38 W. Bal, M. Sokolowska, E. Kurowska and P. Faller, *Biochim. Biophys. Acta*, 2013, **1830**, 5444–5455.
- 39 N. Limjunyawong, J. Fallica, A. Ramakrishnan, K. Datta, M. Gabrielson, M. Horton and W. Mitzner, *J. Vis. Exp.*, 2015, **95**, 52216.
- 40 J. Fallica, S. Das, M. Horton and W. Mitzner, *J. Appl. Physiol.*, 2011, **110**, 1455–1459.





- 41 R. Robinot, M. Hubert, G. D. de Melo, F. Lazarini, T. Bruel, N. Smith, S. Levallois, F. Larrous, J. Fernandes, S. Gellenoncourt, S. Rigaud, O. Gorgette, C. Thouvenot, C. Trébeau, A. Mallet, G. Duménil, S. Gobaa, R. Etournay, P.-M. Lledo, M. Lecuit, H. Bourhy, D. Duffy, V. Michel, O. Schwartz and L. A. Chakrabarti, *Nat. Commun.*, 2021, **12**, 4354.

